Clinical study on prevention of HBV re‐infection by entecavir after liver transplantation

Abstract

ETV is superior to LAM for preventing HBV re-infection following LT.

High Genetic Barrier Nucleos(t)ide Analogue(s) for Prophylaxis From Hepatitis B Virus Recurrence After Liver Transplantation: A Systematic Review

“…In total, 94 articles were initially identified from the literature search, but only 20 studies (7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26) fulfilled the inclusion criteria ( Figure A1). Of two studies (14,15) from one center in China with overlapping study periods, only the latest one (14) was included in the analysis.…”

“…Six studies were from USA (8,10,12,18,19,21), three from China (7,14,20), two from Spain (13,16), two from Japan (9,25) and one study from Netherlands (17), India (23), Taiwan (22) and Greece (11). Eleven studies evaluated the combination of HBIG with hgbNA(s) (7,9,10,(12)(13)(14)16,18,19,22,25), while eight studies (8,11,(17)(18)(19)(20)(21)23) evaluated patients under hgbNA(s) after HBIG discontinuation or without any HBIG (Figure 1). There was only one randomized controlled trial (10), while seven were prospective cohort (7,11,12,17,18,21,23) and nine retrospective cohort studies (8,9,13,14,16,19,…”

“…Of two studies (14,15) from one center in China with overlapping study periods, only the latest one (14) was included in the analysis. Moreover, there were two other studies (20,24) from another center in China with overlapping study periods, but we decided to include the oldest one (20), which was published as full paper, because it provided more details on antiviral prophylaxis.…”

Controversies Regarding the Hepatitis B Immune Globulin Prophylaxis (HBIG) for Liver Transplantation Recipients

“…ComposVarela/2011 [38] Cai/2012 [147] Di Costanzo/2013 [22] Gao [103] Hwang/2011 [97] Hwang/2008 [98] Hu/2012 [148] Ishigami/2011 [149] Kim/2013 [104] Jiménez-Pérez/2010 [93] McGonigal/2013 [101] Perrella/2012 [56] Perrakis/2013 [100] Perrillo/2013 [150] Roche/2010 [28] Tanaka/2012 [102] Teperman/2010 [57] Ueda/2013 [151] Varghese/2014 [105] Xie/2010 [95] Xi/2009 [100] Yasunaka/2011 [46] antiviral NAs and further studies needed to test their effectiveness as part of combination therapy with HBIG and/or montherapy strategies [78][79][80] .…”

Untitled

“…[5][6][7][8] In the last 2 decades, with the advent of hepatitis B immunoglobulin (HBIg) and antiviral drugs as prophylaxis against HBV recurrence after liver transplants, the HBV reinfection and 5-year patient mortality rates have been reduced to 10% and 20%. 9,10 Hepatitis B immunoglobulin prophylaxis in combination with the nucleoside/nucleotide analogs (NAs) lamivudine or tenofovir is a well-accepted treatment recommended by many centers for prevention of HBV reinfection after liver transplants. 11 However, there is no consensus on a standard prophylactic method, and controversy over the duration, dose, and route of administration of HBIg exists among transplant centers.…”